Flu vaccine preserves your eyes against glaucoma:  Influenza A/Flu (H1N1) vaccine-based therapy for glaucoma: Influenza A/Flu (H1N1) vaccine increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down-regulation of its target gene, 20/July/2018,   9.05 am

Flavonoid your way to decrease blood pressure/sugar and extend lifespan: Quercetin-based Lifespan and healthspan extension therapy: Quercetin,  a flavonoid isolated from elder berries and onions, decreases blood sugar and blood pressure levels and prolongs mammalian life span, via down regulation of angiotensin II type I receptor (AT1R), 18/July/2018, 7.47 am
July 18, 2018
Flu vaccine for normalizing blood sugar levels: Influenza A/Flu (H1N1) vaccine-based therapy for blood sugar disease: Influenza A/Flu (H1N1) vaccine increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of  its target gene Lin28, 20/July/2018, 9.39 am
July 20, 2018
Show all

Introduction: What they say

A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes Medical Institute, Bar Harbor, ME 04609, USA shows that “Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice.” This research paper was published, in the 9 February 2017 issue of the journal “Science” [One of the best research journals in “General science” with an I.F of 34.661], by Prof. Simon W. M. John and Pete A. Williams and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Flu vaccine preserves your eyes against glaucoma:  Influenza A/Flu (H1N1) vaccine-based therapy for glaucoma: Influenza A/Flu (H1N1) vaccine increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down-regulation of its target gene


From the significance of the study to public health relevance:

Given that: (1) Glaucoma is a neurodegenerative disease; (2) more than 80 million people worldwide are affected by Glaucoma; (2) Glaucoma is the second leading cause of blindness; (3) Glaucoma has no cure; (4) vision loss due to glaucoma is irreversible; (5) the global economic cost spent for Glaucoma treatment is enormous, there is an urgent need to find: (i) a way to induce regeneration of ganglion cells that were lost in Glaucoma; (ii) a cheaper alternative to the existing expensive anti-glaucoma drugs; (iii) a side-effect-free natural product-based drug; and (v) a way to cure, not just treat, Glaucoma permanently.


What is known?

Prof.Simon’s research team has recently shown that:(1) glaucoma-prone mice suffer from mitochondrial abnormalities, resulting in neuronal dysfunction; (2) NAD+ levels decrease with age; (3) administration of Niacin/Vitamin-B3 protects against glaucoma; (4) expression of Nmnat1, a key NAD+-producing enzyme, protects against glaucoma, suggesting that increasing the expression of Nmnat1 in glaucoma patients may alleviate glaucoma.


From research findings to Therapeutic opportunity:

This study suggests, first the first time, Influenza A/flu(H1N1) vaccine-based therapy, with detailed mechanistic insights, for glaucoma. Influenza A (H1N1)-vaccine  has been shown to protect against cardiovascular diseases, stroke, and others. However, the mechanism of action remains largely unknown.

Influenza A/Flu (H1N1), by increasing the expression of its target gene, it may increase the expression of Nmnat1. Thereby, it may: (1) increase NAD+ levels; (2) decrease Intraocular pressure; (3) improve pressure-induced damage; (4) increase insulin sensitivity; and (5) alleviate glaucoma (Fig.1). Thus, TB vaccine (BCG) either alone or in combination with other drugs, may be used to treat glaucoma or protect against glaucoma. Given the mechanistic insights as to how Influenza A/Flu (H1N1) may function as an anti-glaucoma agent, diabetologists, ophthalmologists, and general practitioners may consider vaccinating their glaucoma patients with Influenza A/Flu (H1N1) or begin a clinical trial. 

Figure 1. Mechanistic insights into how  Influenza A/Flu (H1N1) vaccine attenuates glaucoma. Influenza A/Flu (H1N1) vaccine, by increasing the expression of its target gene, enhances NAD+ levels and improves glaucoma

Figure 2.  Influenza A/Flu (H1N1) vaccine functions as an anti-glaucoma agent by increasing NAD+ levels

 

 

 

 

 

 

 

 

 


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by Dr. L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How TB vaccine (BCG) increase the levels of NAD+

Amount: $500#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, L., Flu vaccine preserves your eyes against glaucoma:  Influenza A/Flu (H1N1) vaccine-based therapy for glaucoma: Influenza A/Flu (H1N1) vaccine increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down-regulation of its target gene, 20/July/2018,   9.05 am, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.